ergoline and Torticollis

Lisuride hydrogen maleate, 0.4 to 5 (mean, 3) mg/d, was given orally to 42 subjects with various types of dystonia. In seven of the eight patients who improved (one with segmental dystonia, one with myoclonic dystonia, two with spasmodic torticollis, two with cranial dystonia, and two with tardive dystonia), the response was confirmed by double-blind placebo substitution. No patients with a suspected structural brain lesion improved. There was no consistent pattern of response among those patients with different forms of idiopathic (primary) dystonia. Lisuride improved some patients, but had no effect on other, apparently identical, patients.

Topics: Administration, Oral; Adult; Age Factors; Aged; Clinical Trials as Topic; Double-Blind Method; Dystonia; Dystonia Musculorum Deformans; Ergolines; Female; Humans; Lisuride; Male; Middle Aged; Torticollis

Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Dystonia; Ergolines; Humans; Lisuride; Middle Aged; Spasm; Torticollis

Topics: Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Humans; Male; Middle Aged; Placebos; Torticollis

Eleven patients who presented with predystonic syndrome later developed pure dystonic syndromes and later developed parkinsonism. This suggests that dystonic syndromes can be the precursor to a mixed syndrome including both dystonia and parkinsonism. While the parkinsonian features in such patients respond to either levodopa or direct-acting agonists, levodopa often exacerbates the underlying dystonia. Direct acting agonists appear to be less liable to do this.

Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis

Topics: Animals; Basal Ganglia Diseases; Chorea; Corpus Striatum; Dystonia; Ergolines; Female; Humans; Lisuride; Male; Middle Aged; Parkinson Disease; Rats; Syndrome; Torticollis